Zoetis Reports 4% Revenue Growth in Latest 10-Q

By Greg Peters • Tuesday, August 05 15:45 • Permanent Link

Zoetis Inc. has recently released its 10-Q report, revealing a snapshot of its financial performance and operational environment. The company, founded in 1950 and headquartered in Parsippany, New Jersey, is a global leader in the animal health industry, focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for both livestock and companion animals.

In the latest 10-Q report, Zoetis reported total revenue of $2.46 billion for the three months ended June 30, 2025, marking a 4% increase compared to the same period in 2024. For the six months ended June 30, 2025, the company reported total revenue of $4.68 billion, representing a 3% increase compared to the same period in 2024.

The company's net income attributable to Zoetis was $718 million for the three months ended June 30, 2025, a 15% increase from the same period in 2024. For the six months ended June 30, 2025, net income attributable to Zoetis was $1.35 billion, reflecting a 10% increase compared to the same period in 2024.

Zoetis operates through two geographic operating segments: the United States and International. The company directly markets its products to veterinarians and livestock producers in approximately 45 countries across North America, Europe, Africa, Asia, Australia, and South America. Additionally, the company has collaborations with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.

The report also highlighted the company's efforts to manage its operating environment, including factors such as tariffs and trade protection measures, disease outbreaks, and foreign exchange rates. Zoetis noted that approximately 41% of its revenue for the six months ended June 30, 2025, was denominated in foreign currencies, exposing the company to changes in foreign exchange rates.

Furthermore, Zoetis provided an analysis of its financial statements, detailing the changes in revenue, costs and expenses, and the impact of various factors on its financial performance.

The market has reacted to these announcements by moving the company's shares -3.87% to a price of $145.94. For more information, read the company's full 10-Q submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.